Loading...
•
Dec 31, 2025
Viking Therapeutics Q4 2025 Earnings Report
Viking Therapeutics reported significantly higher R&D expenses in the fourth quarter of 2025, resulting in a wider net loss compared to the prior year period.
Key Takeaways
In Q4 2025, Viking reported no revenue and a net loss of $157662000, or $1.38 per share, primarily driven by research and development expenses of $153459000 as the company advanced its obesity pipeline. The company ended the quarter with $706000000 in cash, cash equivalents and short-term investments.
Net loss for Q4 2025 was $157662000, or $1.38 per share.
Research and development expenses increased to $153459000 from $30987000 year over year.
General and administrative expenses declined to $11279000 from $15251000.
Cash, cash equivalents and short-term investments totaled $706000000 at quarter end.
Forward Guidance
Viking highlighted continued advancement of its obesity pipeline, including ongoing Phase 3 VANQUISH trials for VK2735, plans to initiate Phase 3 development for oral VK2735 in 3Q26, and an IND filing for a dual amylin agonist in 1Q26.
Positive Outlook
- Phase 3 VANQUISH-1 enrollment completed ahead of schedule.
- Oral VK2735 expected to enter Phase 3 in 3Q26.
- Maintenance dosing study fully enrolled with data expected in 3Q26.
- Planned IND filing for dual amylin agonist in 1Q26.
- Strong quarter-end cash position of $706000000.
Challenges Ahead
- Significant increase in R&D expenses year over year.
- Net loss widened substantially compared to Q4 2024.
- No product revenue generated.
- High ongoing clinical development spending expected.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...